MoonLake Immunotherapeutics
MLTX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001821586
In the last 90 days, MoonLake Immunotherapeutics insiders filed 0 open-market purchases and 5 sales; 172 institutions reported holding it in 13F filings for Q2 2026, worth $1.43B in total; no superinvestor holds it.
Q2 2021 vs. Q1 2021
How the institutions holding MoonLake Immunotherapeutics changed between Q1 2021 and Q2 2021.
All holders in Q2 2021All holders in Q1 2021
| Measure | Q1 2021 | Q2 2021 | Change |
|---|---|---|---|
| Holders | 42 | 46 | +4 |
| Shares | 10.7M | 11.2M | +526.2K (+4.9%) |
| Value | $108.9M | $115.8M | +$6.86M (+6.3%) |
New holders (6)
Institutions that held MoonLake Immunotherapeutics at the end of Q2 2021 but not at the end of Q1 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Finepoint Capital LP | 350,000 | $3.62M | 0.68% |
| Picton Mahoney Asset Management | 70,000 | $725.0K | 0.03% |
| Prelude Capital Management, LLC | 50,000 | $518.0K | 0.03% |
| D. E. Shaw & Co., Inc. | 23,013 | $238.0K | 0.00% |
| UBS Group AG | 374 | $4.00K | 0.00% |
| Tower Research Capital LLC (TRC) | 17 | $0 | 0.00% |
Sold out (2)
Institutions that held MoonLake Immunotherapeutics at the end of Q1 2021 and filed for Q2 2021 without it.
| Institution | Shares, Q1 2021 | Value, Q1 2021 |
|---|---|---|
| HealthCor Management, L.P. | 60,027 | $613.0K |
| Suvretta Capital Management, LLC | 35,344 | $361.0K |